M.A. Molina

3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial

R. Stahel, Urania Dafni, Oliver Gautschi et al. · European Journal of Cancer · 2015 · 28 citations

Belief Trial, Phase Ii Trial, Medicine +9

Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain

Vanessa Bach, Ángel F. Remacha, Albert Altés et al. · Blood Cells Molecules and Diseases · 2005 · 26 citations

Novel Ferroportin 1, Mendelian Disorder, Genetic Disorder +8

Mansonella perstans filariasis in a HIV patient: finding in bone marrow.

M.A. Molina, MT Cabezas, María-José Giménez · PubMed · 1999 · 17 citations

Parasitic Disease, Lymphatic Filariasis, Pathology +6

Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

Rafael Rosell, B. Massuti Sureda, Carlota Costa et al. · Annals of Oncology · 2012 · 17 citations

Overall Survival, Medicine, Egfr L858r +9

Self‐Assembled Peptide‐Gold Nanoclusters with SiRNA Targeting Telomeric Response to Enhance Radiosensitivity in Lung Cancer Cells

Sean Moro, Sule Erbek, Muriel Jourdan et al. · Small Science · 2024 · 10 citations · Full text